A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Key facts
- Where
- Abington, Atlanta, Austin, Boulder, Brandon, Canton, Cincinnati, Colorado Springs, Columbia, Cullman, Dallas, Denver, Dublin, Huntersville, Kansas City, Lansing, Lincoln, Little Rock, Los Angeles, Macon, Madison, Miami, Middletown, Peoria, Phoenix, San Antonio, San Francisco, Stanford, Sterling Heights, Stockbridge, Sugar Land, Winter Park, and Wyomissing, United StatesSee the 33 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06767683, who can take part
Where in United States
- Abington, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Atlanta, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Austin, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Boulder, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Brandon, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Canton, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Cincinnati, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Colorado Springs, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Columbia, South CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Cullman, AlabamaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Dallas, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Denver, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Dublin, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Huntersville, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Kansas City, KansasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Lansing, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Lincoln, NebraskaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Little Rock, ArkansasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Macon, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Madison, WisconsinHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Miami, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Middletown, New JerseyHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Peoria, IllinoisHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Phoenix, ArizonaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- San Antonio, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- San Francisco, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Stanford, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Sterling Heights, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Stockbridge, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Sugar Land, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Winter Park, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Wyomissing, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Alkermes, Inc.
- Trial code
- NCT06767683EU 2024-519822-18-00
- Record updated
- 9 October 2026
- Original description
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.Read full original descriptionShow less
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
Inclusion: Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1); Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects).
Exclusion: Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening; Developed a new clinically significant health condition, ECG or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study; Is currently pregnant, breastfeeding, or planning to become pregnant during the study.